- Home
- GTEC vs KPRX Comparison
GTEC vs KPRX Comparison
Compare GTEC & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | KPRX |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.7M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GTEC | KPRX |
|---|---|---|
| Price | $0.83 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 238.6K | 17.8K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $90,694,007.00 | N/A |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.09 | ★ N/A |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $0.47 | $1.76 |
| 52 Week High | $1.61 | $2.95 |
Technical Indicators
Market Signals| Indicator | GTEC | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 83.04 | 46.58 |
| Support Level | $0.64 | $2.43 |
| Resistance Level | $0.95 | $2.61 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 93.67 | 47.83 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.